Evotec / ENS Holdings

MCF advised Evotec AG, a leader in the discovery of small molecule drugs, on the acquisition of the remaining 78% of ENS Holdings, Inc., which discovers and develops therapeutics for the treatment of Alzheimer’s disease and other Central Nervous System disorders with high unmet medical needs. The acquisition was financed by way of a PIPE transaction.